Peptide reference · Library entry
Tesamorelin
Egrifta WR
Approved product
Status as of
Hormones
Reading note
Consider the path from the population named in a claim to the people whose observations appear in the analysis. Eligibility rules, recruitment and continued observation are different steps to examine. If a hypothetical report includes only a selected portion of an initial group, identify the selection rule before extending the conclusion. This does not automatically invalidate the result. It helps define the question the result can address and the additional information needed to discuss people outside that observed group with appropriate care.
Approval scope
Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.
Mechanism
Stimulates growth-hormone release.
Evidence
A randomized trial measured visceral fat.
Limitations
Not for weight management.
Safety context
Active malignancy is a contraindication.
Formulation and route
Specified subcutaneous formulation.
Questions to take to the evidence
- How were the people represented in the analysis selected?
- Which selection steps occur between initial eligibility and the final observation?
- What information would support applying the conclusion beyond the observed group?
Sources
- EGRIFTA WR
NLM · Checked
- Falutz trial
PubMed · Checked
Connect the next question
Educational reference. AI-assisted editorial content; no independent human medical review. This library does not provide prescribing or self-treatment instructions.